Results 111 to 120 of about 91,896 (245)

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3‐Mutated AML: A FILO‐DATAML‐PETHEMA Real‐World Study

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC (n ...
Gaspar Aspas Requena   +31 more
wiley   +1 more source

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti‐apoptotic protein MCL1. In an investigator‐sponsored, open‐label, phase Ib study (NCT03955783), adult patients with relapsed or ...
Somedeb Ball   +11 more
wiley   +1 more source

Judicial Perspectives on Neurodiversity in Queensland Courts, Tribunals and Commissions: Experiences With Disclosure and Witness Credibility

open access: yesAustralian Journal of Social Issues, EarlyView.
ABSTRACT Little is known about the impacts of the disclosure, or the non‐disclosure, of medical conditions associated with neurodiversity in the context of court proceedings and hearings before tribunals and commissions. This paper examines the experiences of twenty‐three Queensland Judges, Magistrates, and Tribunal and Commission Members with ...
Danielle Bozin   +5 more
wiley   +1 more source

Spin Regulation of Fe Single Site Induced by Adjacent Mg Site Achieving Excellent Oxygen Reduction Catalysis. [PDF]

open access: yesNanomicro Lett
Shi Y   +12 more
europepmc   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

open access: yesHepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou   +13 more
wiley   +1 more source

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

open access: yesHepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai   +29 more
wiley   +1 more source

Home - About - Disclaimer - Privacy